Navigation Links
Sinovac Reports Unaudited Second Quarter Financial Results
Date:8/14/2014

100.0%

27,504

100.0%Cost of goods sold6,303

24.6%

6,853

24.9%Gross profit19,333

75.4%

20,651

75.1%Total sales for the first half of 2014 were $25.6 million, a decrease of 6.8% from $27.5 million in the same period of 2013. Sales for the first half of 2014 were impacted by decreased sales of the Company's hepatitis A vaccine, Healive, as a result of the challenging environment in the private-pay market.

Gross profit for the first half of 2014 was $19.3 million, a decrease of 6.4% from $20.7 million in the same period of 2013. Gross margin was 75.4% in the first half of 2014, compared to 75.1% in the same period of 2013.

Selling, general and administrative expenses for the first half of 2014 were $16.4 million, compared to $15.9 million for the same period of 2013.

R&D expenses in the first half of 2014 were $5.0 million, compared to $3.9 million in the same period of 2013. These expenses are primarily related to the continued advancement of pipeline vaccine candidates.Net loss attributable to stockholders in the first half of 2014 was $2.2 million or $(0.04) per basic and diluted share, compared to a net loss of $0.7 million, or $(0.01) per basic and diluted share, in the same period of 2013.

As of June 30, 2014, cash and cash equivalents totaled $89.6 million, compared to $107.2 million as of December 31, 2013. Net cash used in operating activities was $11.4 million during the first half of 2014. Net cash used in investing activities was $5.7 million, which was primarily used for payment
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
2. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
5. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
6. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
7. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
8. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
9. MarketResearch.com: New Biotechnology Market Research Reports Added to Kalorama Information Knowledge Center
10. GenVec Reports Second Quarter 2014 Financial Results
11. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... -- Intrexon Corporation (NYSE: XON ), a leader ... previously announced public offering of common stock, including the ... to purchase an additional 731,707 shares of common stock ...  The exercise of the underwriters, option brought the total ... to 5,609,756 shares and increased the total gross proceeds ...
(Date:8/26/2015)... San Bruno, CA. (PRWEB) , ... August 26, 2015 , ... ... three major conferences to develop new business relationships with local sponsors in southern California. ... services to facilitate their drug development processes and regulatory pathways., , ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... ... C completes ... - Rights to TRAIL receptor antibodies reacquired - ... development for the treatment of atherosclerosis -, ROCKVILLE, Md., May 5 Human ...
... EDMONTON, May 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: ... (MS), will hold,its Annual General Meeting on Friday, May ... A live audio webcast of the conference call will ... ten minutes prior to the,conference call to ensure adequate ...
... Cequent Pharmaceuticals, a,pioneer in the development ... prevent and treat human disease, announced that ... board of directors. Dr. Taylor is,president and ... a,Cambridge, Massachusetts-based biotechnology company developing novel,classes of ...
Cached Biology Technology:Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 9BioMS Medical announces conference call and web cast for Annual General Meeting 2Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals' Board of Directors 2
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... of Harvard and MIT today announced that they have ... from the National Institutes of Health (NIH) to identify ... can probe the proteins, signaling pathways and cellular processes ... Broad Institute is among nine institutions to receive funding ...
... America,s population, diabetes can lead to blindness, kidney failure, strokes ... new cure based on advances in cell therapy ... TAU,s Sackler Faculty of Medicine, whose research group is among ... to cultivate cells derived from insulin-producing beta cells from human ...
... Spanish . , Background , Many ... in childhood or adolescence. In fact some studies show that ... diagnostic criterion for a mental disorder before reaching adulthood. The ... serious in children than in adults in fact, childhood ...
Cached Biology News:Broad Institute awarded grant to develop chemical probes for human biology and disease 2Broad Institute awarded grant to develop chemical probes for human biology and disease 3Battling diabetes with beta cells 2Risks and benefits of antipsychotics in children and adolescents 2Risks and benefits of antipsychotics in children and adolescents 3Risks and benefits of antipsychotics in children and adolescents 4Risks and benefits of antipsychotics in children and adolescents 5
...
Anti Autotaxin /ENPP2 , - (Rabbit)...
...
... An N-nitroso-containing diabetogenic compound that acts ... pancreatic islets. An antibiotic effective against ... DNA strand breaks in pancreatic islet ... in H 2 O. RTECS LZ5775000, ...
Biology Products: